Search results for "Liver"

showing 10 items of 4961 documents

Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.

2018

medicine.medical_specialtyHepatologyWaiting Listsbusiness.industrymedicine.medical_treatmentHepatitis C virusAdministration OralLiver transplantationHepatitis C Chronicmedicine.disease_causeAntiviral AgentsLiver Transplantation03 medical and health sciences0302 clinical medicineWaiting list030220 oncology & carcinogenesisInternal medicineMedicineHumans030211 gastroenterology & hepatologyDelisting Direct-acting oral antivirals Hepatitis C virus Liver transplantation Organ allocation WaitlistingbusinessJournal of hepatology
researchProduct

Barbiturate jaundice

1969

Summary A case of barbital-induced jaundice is described. The patient, a 31-year-old woman, developed generalized skin eruption, mucosal lesions, and fever 2 hr after the ingestion of 2 tablets of a barbital-containing drug (Veramon). She then developed a deep cholestatic jaundice which lasted more than 7 months. During the remission of jaundice, a rechallenge with phenobarbital caused a recurrence of fever and skin eruption, with exacerbation of jaundice.

medicine.medical_specialtyHepatologybiologyExacerbationmedicine.diagnostic_testbusiness.industrymedicine.drug_classGastroenterologyJaundiceBarbitalGastroenterologyAlanine transaminaseBarbiturateAnesthesiaInternal medicinebiology.proteinMedicineIngestionPhenobarbitalmedicine.symptombusinessLiver function testsmedicine.drugGastroenterology
researchProduct

P0760 : PNPLA3 rs738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C

2015

medicine.medical_specialtyHepatologybiologybusiness.industryHepacivirusFatty liverHepatitis Cmedicine.diseasebiology.organism_classificationGastroenterologyObesityMembrane proteinInternal medicineGenotypebiology.proteinMedicineLipaseSteatohepatitisbusinessJournal of Hepatology
researchProduct

On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis

2020

medicine.medical_specialtyHepatologybusiness.industryBiopsyReproducibility of ResultsNon alcoholicmedicine.diseaseGastroenterologyText miningLiverNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineHumansSteatohepatitisLiver histologybusinessValue (mathematics)Randomized Controlled Trials as TopicJournal of Hepatology
researchProduct

MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease

2014

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseaseMERTKmedicine.diseaseGastroenterologyInternal medicineGenotypeLower prevalencemedicineSteatosisbusinessDigestive and Liver Disease
researchProduct

Chronic Intermittent Hypoxia is associated with Liver Damage and Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease

2015

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineChronic intermittent hypoxiaIn patientLiver damagebusinessDigestive and Liver Disease
researchProduct

Hyperuricemia in non-alcoholic fatty liver disease: authors’ reply

2011

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinePharmacology (medical)HyperuricemiabusinessAlimentary Pharmacology & Therapeutics
researchProduct

Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease

2011

SUMMARY Background Hyperuricemia has been associated with metabolic disorders. In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD). Mean uric acid serum level was 5.75 mg ⁄ dL, and about 20% of patients had hyperuricemia, that was independently associated with younger age (OR 0.951, 95% CI 0.918-0.984, P = 0.004), lobular inflammation (OR 2.144, 95% CI 1.055-4.357, P = 0.03) and steatosis grade (OR 1.859, 95% CI 1.078-3.205, P = 0.02), by multivariate logistic regression analysis. Female gender (OR 2.656, 95% CI 1.190-5.928, P = 0.01), higher HOMA index (OR 1.219, 95% CI 1.043- 1.4…

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseLogistic regressionGastroenterologyEndocrinologyInternal medicineMedicinePharmacology (medical)In patientHyperuricemiaLiver damageSteatosisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

P1013 : Chronic intermittent hypoxia is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease

2015

all the steatosis grades, except S2 vs S3. The diagnostic performances of CAP in quantifying each steatosis grade was: for S ≥1 AUC=0.813 (cutoff 260dB/m, Se = 64.84%, Sp =87.27%, PPV=80.8%, NPV=75%, +LR =5.09, −LR =0.40, DA=76.11%); for S ≥2 AUC=0.822 (cutoff 285dB/m, Se = 69.70%, Sp =85.12%, PPV=47.9%, NPV=93.5%, +LR =4.68, −LR =0.36, DA=82.08%); for S ≥3 AUC=0.838 (cutoff 294dB/m, Se =83.33%, Sp =82.54%, PPV=23.3%, NPV=98.7%, +LR =4.77, −LR =0.20, DA=81.59%). AUCs calculated between two steatosis grades only were: 0.772 (for S0 vs S1), 0.874 (S0 vs S2), 0.904 (S0 vs S3), 0.659 (S1 vs S2), 0.777 (S1 vs S3), and 0.665 (S2 vs S3) respectively. Conclusions: Maximal diagnostic accuracy could …

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineCutoffChronic intermittent hypoxiaIn patientLiver damageSteatosisbusinessJournal of Hepatology
researchProduct

Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non‐alcoholic fatty liver disease—the role for non‐invasive testing

2021

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon invasiveGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyText miningInternal medicinemedicinePharmacology (medical)In patientbusinessHepatic fibrosisCoronary atherosclerosisAlimentary Pharmacology & Therapeutics
researchProduct